Pajjiż: Singapor
Lingwa: Ingliż
Sors: HSA (Health Sciences Authority)
IRBESARTAN
SANOFI-AVENTIS SINGAPORE PTE. LTD.
C09CA04
75.00 mg
TABLET, FILM COATED
ORAL
Prescription Only
SANOFI WINTHROP INDUSTRIE
1999-04-06
APROVEL LOGO _[75mg, 150mg, 300mg]_ Film-coated tablet Irbesartan _[SANOFI LOGO] _ COMPOSITION APROVEL 75 MG FILM-COATED TABLETS Each film-coated tablet contains 75 mg irbesartan. APROVEL 150 MG FILM-COATED TABLETS Each film-coated tablet contains 150 mg irbesartan. APROVEL 300 MG FILM-COATED TABLETS Each film-coated tablet contains 300 mg irbesartan. PHARMACEUTICAL FORM 75 MG FILM-COATED TABLET White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side. 150 MG FILM-COATED TABLET White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side. 300 MG FILM-COATED TABLET White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 engraved on the other side. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive drug regimen _(see Pharmacodynamic properties)._ POSOLOGY AND METHOD OF ADMINISTRATION The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Aprovel at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years. In patients insufficiently controlled with 150 mg once daily, the dose of Aprovel can be increased to 300 mg, or other anti-hypertensive agents can be added. In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Aprovel _(see Interaction with other _ _medicinal products and other forms of interaction). _ In hypertensive type 2 diabetic patients Aqra d-dokument sħiħ